



January 5, 2021  
JCR Pharmaceuticals Co., Ltd.

Translation

## **JCR Initiates Operation of “Bio Research Center”**

January 5, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today to the initiation of operation for new research facility “Bio Research Center”.

JCR obtained this facility in July 2019 and has been preparing for operation since then in order to expand the capacity of research projects, research staff, and to strengthen our capabilities for new drug development. JCR is also strengthening its R&D capabilities as a consequence to one of our important business challenges which is “Exploring new therapeutic targets in addition to lysosomal storage diseases: Expansion of basic research activities”.

JCR will accelerate the R&D activities for new biologics as our core strength consisting of three modalities: Recombinant protein therapeutics, cell therapy/regenerative medicine and gene therapies. Furthermore JCR will strengthen collaborations with academia as part of its promotion of translational research.

### ■ Key information

Name : Bio Research Center  
Location : 1-5-4, Murotani, Nishi-ku, Kobe city  
Area : 10,584.40 m<sup>2</sup>



As a specialty pharma engaged in the development of pharmaceutical products for rare diseases, JCR will continue to strengthen business activities in the future and continue to overcome challenges without compromise to deliver the new value-adding medicines based on our original technology platforms to reach as many patients as possible.

### **[About JCR Pharmaceuticals]**

JCR is a specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical

products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

**[Cautionary Statement Regarding Forward-Looking Statements]**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

END

###